Nautilus Biotechnology, Inc. NAUT
0.96
(0.03)
(3.03%)
as of 25 Sep
- Market cap
- $126.1M
- P/E
- 0.0×
Follow NAUT
Insider Buys
alert about insiders buying in the last 12 month
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | — | 25.73 | 60.09 | 27.57 | 19.39 | 17.40 | 13.33 |
Net Debt/EBITDA |
— | — | 5.85 | 7.28 | 3.02 | 2.37 | 1.67 | 1.67 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | — | 0.90 | 0.78 | 0.79 | 0.81 | 0.84 | 0.86 |
Capex/Depreciation |
— | — | (0.35) | (0.75) | (0.92) | (0.80) | (0.58) | (0.25) |
Interest Coverage |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | — | (9.36%) | (30.14%) | (17.07%) | (21.95%) | (29.86%) | (32.27%) | |
| — | 0.00% | (36.75%) | (20.81%) | (15.48%) | (19.42%) | (25.82%) | (27.20%) | |
ROIC |
— | — | 0.00% | (176.84%) | (30.48%) | (51.77%) | (64.59%) | (77.98%) |
Return on Tangible Assets |
— | — | (20.55%) | (14.55%) | (31.46%) | (37.02%) | (54.75%) | (58.15%) |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | — | (0.51) | (0.49) | (0.39) | (0.43) | (0.49) | (0.41) |
Cash per Share |
— | — | 2.64 | 4.09 | 1.48 | 1.39 | 1.04 | 0.82 |
Shareholders Equity per Share |
— | — | (1.02) | 4.30 | 2.53 | 2.12 | 1.66 | 1.24 |
Interest Debt per Share |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | — | (1.02) | 4.30 | 2.53 | 2.12 | 1.66 | 1.24 |
Free Cash Flow |
— | — | (14.92) | (41.51) | (48.13) | (54.15) | (61.27) | (51.97) |
Working Capital |
— | — | 74.64 | 343.41 | 180.42 | 167.72 | 125.19 | 98.01 |
Capital Expenditures |
— | — | (0.92) | (2.27) | (2.32) | (2.44) | (2.12) | (1.28) |
Net Current Asset Value |
— | — | (37.07) | 314.35 | 152.08 | 136.63 | 98.81 | 71.82 |
| Other line items | ||||||||
Quick Ratio |
— | — | 25.43 | 59.49 | 27.16 | 19.01 | 17.02 | 13.00 |
Depreciation/Fixed assets |
— | — | 1.92 | 1.22 | 0.68 | 0.71 | 0.89 | 1.46 |
Cash ROIC |
— | — | (32.68%) | (5.88%) | (9.91%) | (12.76%) | (18.67%) | (20.80%) |
Accounts Payable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | — | (0.48) | (0.46) | (0.37) | (0.41) | (0.47) | (0.40) |
Capex per Share |
— | — | (0.03) | (0.03) | (0.02) | (0.02) | (0.02) | (0.01) |
Average Payables |
— | — | 1.10 | 1.10 | 1.50 | 1.46 | 1.31 | 0.97 |
Average Assets |
— | 0.00 | 42.51 | 241.73 | 374.25 | 327.81 | 274.15 | 216.93 |
Average Common Equity |
— | — | 166.93 | 166.93 | 339.25 | 290.14 | 237.04 | 182.85 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates